GW Pharmaceuticals PLC Sponsored ADR
(NASDAQ : GWPH)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
AMRNAmarin Corporation Plc Sponsored ADR
-0.46%17.252.0%$248.04m
SHPGShire PLC Sponsored ADR
0.58%176.620.4%$238.61m
JAZZJazz Pharmaceuticals Plc
1.59%145.472.2%$112.05m
PRGOPerrigo Co. Plc
-3.57%60.556.8%$101.21m
ENDPEndo International Plc
0.72%12.558.9%$64.25m
GWPHGW Pharmaceuticals PLC Sponsored ADR
-2.06%122.816.3%$61.46m
MNKMallinckrodt Plc
-9.14%28.0021.1%$55.28m
SAGESAGE Therapeutics, Inc.
-1.19%108.409.6%$55.20m
ICPTIntercept Pharmaceuticals, Inc.
2.02%105.9318.7%$53.65m
HZNPHorizon Pharma plc
-7.16%20.637.4%$53.18m
UTHRUnited Therapeutics Corporation
-2.66%113.4214.4%$47.80m
CTLTCatalent Inc
-0.61%37.492.4%$41.91m
PTLAPortola Pharmaceuticals, Inc.
-1.09%19.137.7%$32.91m
ICLRICON Plc
-0.16%127.744.1%$32.13m
AERIAerie Pharmaceuticals, Inc.
-5.92%40.976.9%$29.05m

Company Profile

GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics from proprietary cannabinoid product platform in a broad range of disease areas. It operates through the following segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The Commercial segment distributes and sells the commercial products and promotes Sativex through collaborations with pharmaceutical companies for the currently approved indication of spasticity due to multiple sclerosis. The Sativex Research and Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex, which are using the proprietary cannabinoid technology platform. The company was founded by Geoffrey W. Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom.